- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Alvotech, not content to line up behind other Humira biosims, sues AbbVie over 'wrongful monopoly' | ||
| Di | AstraZeneca shareholders approve CEO Soriot's contentious 2021 pay plan, defying wishes of 4 advisory groups | ||
| Di | Viatris, Organon could merge given similar business models, but one of them already seems more credible: analyst | ||
| Di | 2 ads for 2 audiences: SK Life targets docs and patients in seizure drug campaign | ||
| Di | Pfizer, Regeneron CEOs see extended need for COVID-19 vaccines, treatments as pandemic enters next phase | ||
| Di | With lower COVID-19 cases expected this summer, Eli Lilly to welcome all employees back to Indianapolis HQ | ||
| Di | With cost cuts and asset sales largely wrapped, Takeda gears up for growth: CEO | ||
| Di | Pharma putting digital drug delivery at heart of plans: survey | ||
| Di | Siga seeks FDA approval for intravenous smallpox therapy | ||
| Di | OliX allies with PCI to develop dermatological RNAi therapies | ||
| Di | Pfizer's COVID-19 vaccine scores FDA nod in adolescents, enabling a wider rollout | ||
| Mo | Eli Lilly taps 3 Indian drugmakers to bolster supply of COVID-19 drug baricitinib | ||
| Mo | Pharma industry's reputation hits plateau amid spike in vaccine hesitancy | ||
| Mo | Will a waiver work? Don't expect COVID-19 vaccine patents to lift quickly, if ever, analysts say | ||
| Mo | With $15B COVID-19 vaccine sales in sight, BioNTech aspires to become a 'global immunotherapy powerhouse' | ||
| Mo | Stryker takes a swing at ballpark joint-replacement promos with Minor League partnership | ||
| Mo | BioNTech, Fosun Pharma eye 1B doses of COVID-19 vaccine capacity with new China JV | ||
| Sa | Novo Nordisk recalls sales rep samples sunk by Texas power outages | ||
| Fr | Pfizer, Merck KGaA's Bavencio hits NICE roadblock in bladder cancer coverage | ||
| Fr | Even with the pandemic in retreat, Amgen will let most employees keep working from home | ||
| Fr | Pfizer, AstraZeneca COVID vaccines probed in Europe after reports of heart inflammation, rare nerve disorder | ||
| Fr | AstraZeneca's lagging I-O drug tremelimumab finally pulls through with Imfinzi combo score in lung cancer | ||
| Fr | Another 5 years of dominance: Oncology, immunology will extend their lead as pharma's top fields through 2025 | ||
| Fr | Fierce Pharma Asia-BeiGene touts Q1, PARP inhibitor nod; Astellas culls muscle disease pact | ||
| Do | Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campus |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
